IE
CADL icon

Israel Englander’s Candel Therapeutics CADL Stock Holding History

Israel Englander’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
1,093,905
+33,819
+3% +$255K ﹤0.01% 2169
2026
Q1 		$5.19M Buy
+1,060,086
New +$5.77M ﹤0.01% 2894
2025
Q4 		– Sell
-136,670
Closed -$697K – 6037
2025
Q3 		$697K Buy
+136,670
New +$790K ﹤0.01% 4871
2025
Q2 		– Sell
-208,609
Closed -$1.18M – 5891
2025
Q1 		$1.18M Buy
208,609
+176,983
+560% +$1.45M ﹤0.01% 4235
2024
Q4 		$275K Buy
31,626
+17,914
+131% +$106K ﹤0.01% 5122
2024
Q3 		$95K Sell
13,712
-3,632
-21% -$22.6K ﹤0.01% 5598
2024
Q2 		$108K Buy
+17,344
New +$130K ﹤0.01% 5297
2022
Q4 		– Sell
-14,844
Closed -$47K – 6596
2022
Q3 		$47K Buy
+14,844
New +$50.3K ﹤0.01% 6209
2022
Q1 		– Sell
-13,106
Closed -$102K – 6941
2021
Q4 		$102K Buy
13,106
+2,460
+23% +$23.9K ﹤0.01% 6244
2021
Q3 		$115K Buy
+10,646
New +$88.3K ﹤0.01% 6374

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Israel Englander's CADL Position: Q2 2026 in Review

Israel Englander increased its Candel Therapeutics (CADL) stake by 3.2% in Q2 2026, buying an estimated $255K and bringing the position to 1,093,905 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Israel Englander first reported a position in CADL in Q3 2021 and has held it in 10 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Israel Englander held 1,093,905 shares of Candel Therapeutics worth $11.3M as of Q2 2026.
  • Israel Englander bought 33,819 Candel Therapeutics shares in Q2 2026, an estimated $255K.
  • Candel Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2169 holding.
  • Israel Englander first reported a position in Candel Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.